Literature DB >> 12002257

Pleiotropic effects of HMG-CoA reductase inhibitors.

Nikos Werner1, Georg Nickenig, Ulrich Laufs.   

Abstract

HMG CoA reductase inhibitiors (statins) have been shown to be effective lipid lowering agents and are able to significantly reduce cardiovascular mortality and morbidity in patients at risk for cardiovascular disease. Recent clinical and experimental data suggest that the benefit of statins may extend beyond their hepatic effects on serum cholesterol levels. This review summarizes the current evidence and the molecular mechanisms of the direct effects of statins on plaque stability, inflammation, endothelial function, oxidative stress, thrombosis and stroke. Furthermore, recent data on the effects of statins on bone marrow, bone density and dementia are described. In summary, statins have emerged as a novel and powerful tool to study cardiovascular biology, including protein isoprenylation, small G protein function, leukocyte activity and endothelial progenitor cells. These pleiotropic properties of statins may have important clinical implications in addition to lowering serum cholesterol.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12002257     DOI: 10.1007/s003950200000

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  40 in total

Review 1.  Isoprenoid metabolism and the pleiotropic effects of statins.

Authors:  Ulrich Laufs; James K Liao
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

2.  Hypercholesterolemia promotes an osteoporotic phenotype.

Authors:  Kristine Pelton; Jaclynn Krieder; Danese Joiner; Michael R Freeman; Steven A Goldstein; Keith R Solomon
Journal:  Am J Pathol       Date:  2012-07-04       Impact factor: 4.307

Review 3.  Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease.

Authors:  Maria-Paz Marzolo; Guojun Bu
Journal:  Semin Cell Dev Biol       Date:  2008-10-17       Impact factor: 7.727

4.  Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis.

Authors:  Cynthia M Carlsson; David M Nondahl; Barbara E K Klein; Patrick E McBride; Mark A Sager; Carla R Schubert; Ronald Klein; Karen J Cruickshanks
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jan-Mar       Impact factor: 2.703

5.  Ezetimibe is an inhibitor of tumor angiogenesis.

Authors:  Keith R Solomon; Kristine Pelton; Kelly Boucher; Jinsoo Joo; Christopher Tully; David Zurakowski; Carl P Schaffner; Jayoung Kim; Michael R Freeman
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

6.  Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice.

Authors:  S V V S Ramanjaneyulu; P P Trivedi; S Kushwaha; A Vikram; G B Jena
Journal:  J Physiol Biochem       Date:  2013-02-06       Impact factor: 4.158

7.  Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes.

Authors:  LiJun Wu; LianYou Zhao; QiangSun Zheng; FuJun Shang; XianMei Wang; LiFeng Wang; Bing Lang
Journal:  Mol Cell Biochem       Date:  2006-03-14       Impact factor: 3.396

8.  Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques.

Authors:  Yiannis S Chatzizisis; Michael Jonas; Roy Beigel; Ahmet U Coskun; Aaron B Baker; Benjamin V Stone; Charles Maynard; Ross G Gerrity; William Daley; Elazer R Edelman; Charles L Feldman; Peter H Stone
Journal:  Atherosclerosis       Date:  2008-08-05       Impact factor: 5.162

9.  Simvastatin and GGTI-2133, a geranylgeranyl transferase inhibitor, increase erythrocyte deformability but reduce low O(2) tension-induced ATP release.

Authors:  K M Clapp; M L Ellsworth; R S Sprague; A H Stephenson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-18       Impact factor: 4.733

10.  A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion.

Authors:  S Hooper; C Gaggioli; E Sahai
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.